Hemp THC Loophole: How Delta-8 and Hemp-Derived THC Products Remain Legal

Executive Summary

The "hemp THC loophole" refers to a regulatory gap created by the 2018 Farm Bill that legalized hemp containing no more than 0.3% delta-9 THC by dry weight, inadvertently enabling manufacturers to produce psychoactive products using delta-8 THC, THCA, and other hemp-derived cannabinoids that fall outside the federal definition of marijuana. This loophole has spawned a multi-billion dollar industry of intoxicating hemp products sold in gas stations, smoke shops, and online retailers across the United States, often without the testing requirements, age restrictions, or regulatory oversight applied to state-licensed cannabis programs. The phenomenon has created a complex legal landscape where products that produce marijuana-like effects remain technically legal under federal law while states scramble to regulate or ban them. Recent legislative failures in South Carolina and ongoing regulatory battles in states like Texas, North Carolina, and Ohio demonstrate the challenge lawmakers face in closing this loophole without undermining legitimate hemp industries or contradicting federal statute.

The controversy centers on chemistry and statutory language. While the 2018 Farm Bill explicitly legalized hemp by defining it as cannabis with delta-9 THC concentrations below 0.3%, it did not address other forms of THC or cannabinoids that can be synthesized or concentrated from legal hemp. Manufacturers exploited this gap by extracting THCA (tetrahydrocannabinolic acid), which converts to delta-9 THC when heated, and synthesizing delta-8 THC from CBD through chemical processes. These products can contain total THC levels of 10-30% or higher while remaining compliant with the 0.3% delta-9 THC threshold when measured in their raw form.

Why This Matters

The hemp THC loophole affects an estimated $28 billion market, impacts 38 states without adult-use cannabis programs, and creates regulatory chaos that touches consumers, licensed cannabis operators, hemp farmers, public health officials, and law enforcement nationwide. For the 100+ million Americans living in states without legal recreational marijuana, hemp-derived THC products represent the only legal access to intoxicating cannabinoids—a reality that has driven explosive growth in convenience store and online sales since 2020.

State-licensed cannabis operators view the loophole as an existential threat. Multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries have invested billions in compliance infrastructure, paying effective tax rates exceeding 70% under Internal Revenue Code Section 280E while competing against hemp retailers who face no such burden. In Florida, licensed dispensaries reported a 23% revenue decline in the first quarter of 2025 that industry analysts attributed partly to hemp product competition. The National Cannabis Industry Association has called the loophole "the single greatest threat to regulated markets" in its 2025 policy priorities.

Public health stakeholders express concern about unregulated product safety. Unlike state-licensed cannabis, which typically requires testing for pesticides, heavy metals, residual solvents, and potency verification, hemp-derived THC products often reach consumers without independent laboratory analysis. A 2024 study by the University of Michigan found that 38% of delta-8 THC products purchased from convenience stores contained delta-9 THC levels exceeding legal limits, while 52% showed contamination from synthesis byproducts not found in natural cannabis.

The loophole also creates enforcement nightmares for law enforcement. Officers cannot distinguish legal hemp flower containing high THCA from illegal marijuana through field testing or visual inspection, leading some jurisdictions to effectively decriminalize possession. District attorneys in Texas and Louisiana have dismissed thousands of marijuana possession cases since 2019 because standard testing cannot differentiate the products, creating a de facto legalization in states where lawmakers intended prohibition.

Background and History

The 2018 Farm Bill Foundation

The hemp THC loophole originated on December 20, 2018, when President Donald Trump signed the Agriculture Improvement Act of 2018 into law, removing hemp from Schedule I of the Controlled Substances Act and defining it as cannabis containing no more than 0.3% delta-9 tetrahydrocannabinol on a dry weight basis. The legislation, championed by Senate Majority Leader Mitch McConnell of Kentucky, aimed to support American hemp farmers by legalizing cultivation for fiber, grain, and CBD extraction. The 0.3% threshold came from a 1976 taxonomic paper by Canadian researchers Ernest Small and Arthur Cronquist, who acknowledged the figure was "completely arbitrary" and chosen merely to distinguish fiber cultivars from drug cultivars.

The Farm Bill's authors focused on CBD, the non-intoxicating cannabinoid that had gained mainstream attention following FDA approval of Epidiolex for epilepsy treatment in June 2018. Legislative history shows no substantive discussion of other cannabinoids or the possibility that manufacturers might exploit the narrow definition of THC. The statute amended 21 U.S.C. § 802(16) to exclude hemp from the definition of marijuana, creating a categorical exemption rather than a controlled regulatory framework.

The Delta-8 THC Emergence (2019-2020)

The first wave of loophole exploitation began in late 2019 when chemists discovered they could convert CBD isolate derived from legal hemp into delta-8 THC through a simple isomerization process using acids or catalysts. Delta-8 THC occurs naturally in cannabis at concentrations below 1%, but the synthesis process enabled manufacturers to produce it at scale from the abundant CBD extracted from hemp biomass. The resulting products delivered psychoactive effects similar to delta-9 THC but remained arguably legal because the Farm Bill had not specifically prohibited delta-8.

By mid-2020, delta-8 THC vape cartridges, gummies, and tinctures appeared in smoke shops and convenience stores across the United States. The COVID-19 pandemic accelerated online sales as consumers sought legal alternatives to state-regulated dispensaries. Market research firm Brightfield Group estimated delta-8 THC sales reached $2 billion in 2021, growing from essentially zero in 2019. The rapid expansion occurred without FDA oversight, state regulation, or industry standards for manufacturing practices.

DEA Interim Final Rule (August 2020)

On August 21, 2020, the Drug Enforcement Administration published an Interim Final Rule implementing the Farm Bill's hemp provisions. The rule stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances," creating immediate controversy over whether delta-8 THC derived from CBD constituted a "synthetically derived" cannabinoid. The DEA defined synthetic cannabinoids as those "that do not occur in the cannabis plant" but provided no clarity on cannabinoids that occur naturally in trace amounts but are produced through chemical conversion of legal hemp compounds.

Industry attorneys argued that delta-8 THC derived from hemp-sourced CBD should be considered a hemp derivative rather than a synthetic cannabinoid, falling under the Farm Bill's exemption. The DEA did not pursue enforcement actions, creating a regulatory gray area that manufacturers interpreted as tacit permission to continue operations. This ambiguity persisted through 2021 and 2022 as the delta-8 market expanded nationwide.

THCA and the "Raw Flower" Loophole (2021-2023)

The second major phase of loophole exploitation emerged in 2021 when hemp cultivators began breeding and selling high-THCA flower that remained compliant with the 0.3% delta-9 THC limit when tested in raw form but converted to intoxicating delta-9 THC when smoked or vaporized. This development exploited a fundamental aspect of cannabis chemistry: THCA, the acidic precursor to THC, does not produce psychoactive effects until it undergoes decarboxylation through heat. The Farm Bill's testing protocols measured delta-9 THC in raw plant material, not the total potential THC after decarboxylation.

Hemp farmers in states like Oregon, North Carolina, and Tennessee developed cultivars with THCA concentrations of 15-25% while maintaining delta-9 THC below 0.3% in pre-harvest testing. These genetics, often derived from marijuana strains like Wedding Cake, OG Kush, and Northern Lights, produced effects indistinguishable from traditional marijuana when consumed. By 2023, high-THCA hemp flower represented an estimated $8 billion market segment, sold openly in states without adult-use cannabis programs.

The THCA loophole proved more difficult for regulators to address than delta-8 THC because it involved naturally occurring cannabinoids in plant material rather than synthesized compounds. The USDA's hemp testing protocols, established under 7 CFR § 990, required testing for "total THC" using a formula that converted THCA to delta-9 THC equivalents (delta-9 THC + (THCA × 0.877)). However, the statutory definition in the Farm Bill referenced only delta-9 THC concentrations, creating a conflict between regulatory guidance and federal law that courts have yet to definitively resolve.

State-Level Backlash (2021-Present)

As hemp-derived THC products proliferated, states began enacting restrictions. In May 2021, Alaska became the first state to explicitly ban delta-8 THC, followed by Arkansas, Colorado, Delaware, and Montana by year-end. These early bans typically amended state controlled substances schedules to include "synthetically derived cannabinoids" or specifically listed delta-8 THC alongside delta-9 THC.

Colorado's approach proved particularly significant because the state had both a mature adult-use cannabis program and a substantial hemp industry. In June 2021, Colorado regulators determined that delta-8 THC products required licensing under the state's marijuana regulatory framework, effectively prohibiting unlicensed hemp retailers from selling them. The Colorado Department of Public Health and Environment issued guidance stating that "any product containing a total delta-9 THC concentration of more than 0.3% is marijuana" and that "delta-8 THC is an artificially derived cannabinoid" subject to marijuana regulations.

By January 2024, 17 states had enacted some form of restriction on hemp-derived intoxicating products, though enforcement varied widely. North Dakota banned all "psychoactive cannabinoids" from hemp in 2021. Kentucky, despite being the home state of the Farm Bill's primary sponsor, prohibited delta-8 THC sales in 2023. Oregon required hemp-derived inhalable products to be sold only through licensed cannabis retailers beginning in January 2024.

The Texas Legal Battle (2023-2024)

Texas emerged as a critical battleground in 2023 when the Department of State Health Services attempted to ban delta-8 and other hemp-derived THC products by classifying them as Schedule I controlled substances. In May 2023, Travis County District Court Judge Jan Soifer issued a temporary injunction blocking the ban, ruling that the state's action likely violated the Farm Bill's preemption of state hemp regulations. The case, Hometown Hero CBD v. Texas Department of State Health Services, centered on whether states could prohibit products that federal law had legalized.

In October 2023, Judge Soifer made the injunction permanent, finding that Texas could not ban hemp products that complied with federal law without violating the Supremacy Clause. The ruling stated that "the Farm Bill preempts state law to the extent that Texas law is an obstacle to the accomplishment and execution of the full purposes and objectives of Congress in enacting the Farm Bill." The Texas Attorney General's office appealed, but the Third Court of Appeals upheld the decision in March 2024, creating precedent that emboldened hemp manufacturers nationwide.

The Texas case demonstrated the legal complexity of closing the loophole at the state level. Because Congress had explicitly legalized hemp and preempted state restrictions on its transportation and sale under 7 U.S.C. § 1639o, states faced constitutional challenges when attempting to prohibit hemp-derived products that met the federal definition. This dynamic shifted the regulatory battle to state legislatures, which could potentially define "hemp" more restrictively than federal law for intrastate commerce.

Federal Regulatory Inaction (2020-2025)

Despite the market's explosive growth, federal agencies provided minimal guidance or enforcement through 2025. The FDA issued warning letters to several delta-8 THC manufacturers in 2022 for making unauthorized health claims but did not take action against the products themselves. The agency's position remained that all cannabinoid products intended for human consumption required FDA approval, but it lacked resources to enforce this stance against thousands of manufacturers.

The DEA similarly declined to clarify its August 2020 rule or pursue enforcement actions against hemp-derived THC products. In congressional testimony in March 2024, DEA Administrator Anne Milgram acknowledged the loophole but stated that "the agency's interpretation is that synthetically derived THC remains a Schedule I controlled substance, but we defer to Congress to provide clearer statutory language." This statement effectively punted responsibility back to lawmakers while the market continued expanding.

The USDA focused its hemp oversight on agricultural compliance—ensuring crops tested below 0.3% delta-9 THC at harvest—rather than downstream product manufacturing. The department's National Hemp Report, published in January 2025, documented 73,860 licensed hemp acres nationwide but included no data on THCA concentrations or product diversion into intoxicating goods.

Key Players

Hemp Industry Stakeholders

The U.S. Hemp Roundtable, representing over 1,500 hemp businesses, has advocated for preserving the Farm Bill's hemp definition while supporting "reasonable" regulations for intoxicating products. The organization argues that overly restrictive state laws threaten legitimate hemp farmers and CBD manufacturers who have invested in compliance infrastructure. In 2024 testimony before the House Agriculture Committee, Roundtable President Jonathan Miller stated that "the solution is not to re-prohibit hemp but to establish clear federal standards for intoxicating hemp products that protect consumers while preserving the legal hemp industry."

Individual companies like Hometown Hero CBD, based in Austin, Texas, have become prominent advocates through litigation. The company's successful legal challenge in Texas established precedent that other manufacturers cite when facing state restrictions. Delta-8 THC producer 3Chi, founded in 2019, claims to have sold over 50 million units and has funded lobbying efforts in multiple states to preserve access to hemp-derived cannabinoids.

State-Licensed Cannabis Industry

Multi-state operators have emerged as the loophole's most vocal opponents. The Cannabis Regulators Association, representing state regulatory agencies, issued a resolution in November 2023 calling for federal action to "close the intoxicating hemp loophole that undermines state regulatory frameworks and public health protections." Curaleaf Holdings, the largest MSO by revenue, dedicated a section of its 2024 annual report to "unregulated hemp competition," noting that "the proliferation of intoxicating hemp products sold outside state regulatory frameworks represents a significant headwind to our business."

State cannabis trade associations in Florida, New York, and Illinois have lobbied for restrictions on hemp-derived THC products, arguing that the loophole creates unfair competition. The Florida Cannabis Action Network supported legislation in 2024 that would have required hemp retailers to obtain state licenses and comply with testing requirements equivalent to medical marijuana dispensaries, though the bill failed to advance.

Federal Lawmakers

Representative Mary Miller of Illinois introduced the Hemp and Hemp-Derived Consumer Products Act in March 2024, which would have amended the Farm Bill to define hemp as containing no more than 0.3% "total THC" (including THCA) and prohibited the sale of "intoxicating hemp-derived products" to individuals under 21. The bill gained 47 co-sponsors but did not receive a committee vote before the congressional session ended. Senator Rand Paul of Kentucky opposed the legislation, arguing it would "destroy the hemp industry my state has built" and that states should handle product regulation individually.

The House Agriculture Committee held hearings on hemp regulation in June 2024, where Chairman Glenn Thompson of Pennsylvania acknowledged the loophole but expressed concern that "we must be careful not to throw out the baby with the bathwater and harm legitimate hemp farmers." This tension between preserving agricultural hemp and restricting intoxicating products has paralyzed federal legislative action through mid-2025.

Public Health and Medical Organizations

The American Academy of Pediatrics issued a policy statement in February 2024 opposing the sale of intoxicating hemp products, citing concerns about youth access and lack of regulation. The organization noted that "delta-8 THC and THCA products are marketed with cartoon characters and candy flavors, packaged in ways that appeal to children, and sold without age verification in many jurisdictions." Poison control centers reported a 312% increase in pediatric exposures to delta-8 THC products between 2020 and 2023, according to data from the American Association of Poison Control Centers.

The National Association of Boards of Pharmacy recommended in 2023 that states prohibit the sale of hemp-derived intoxicating products outside of licensed pharmacies or cannabis dispensaries, arguing that "these products should be subject to the same regulatory oversight as other psychoactive substances to ensure consumer safety and appropriate use."

Legal and Regulatory Framework

Federal Statutory Foundation

The legal architecture of the hemp THC loophole rests on the interaction between the Controlled Substances Act (21 U.S.C. § 801 et seq.) and the 2018 Farm Bill's amendments to the Agricultural Marketing Act of 1946 (7 U.S.C. § 1621 et seq.). The Controlled Substances Act, enacted in 1970, placed marijuana in Schedule I, defined as cannabis containing more than 0.3% THC. The 2018 Farm Bill amended this definition by excluding hemp, defined as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis."

This definition created three critical loopholes. First, it specified only "delta-9 tetrahydrocannabinol," not addressing delta-8 THC, delta-10 THC, THC-O, HHC, or other cannabinoids. Second, it measured concentration "on a dry weight basis" in the raw plant, not accounting for THCA that converts to delta-9 THC when heated. Third, it broadly included "all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers" from compliant hemp, which manufacturers interpret as legalizing any cannabinoid derived from legal hemp feedstock.

The Farm Bill also included preemption language in 7 U.S.C. § 1639o, prohibiting states from restricting the interstate transportation or shipment of hemp lawfully produced under a state or USDA plan. This provision has complicated state efforts to ban hemp-derived products, as manufacturers argue that state prohibitions violate federal preemption when applied to products that meet the federal hemp definition.

DEA Scheduling and Interpretation

The DEA's August 2020 Interim Final Rule added a new category to 21 CFR § 1308.11(d) for "tetrahydrocannabinols," stating that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances." The rule defined "synthetically derived" as "a substance that has been created by a chemical reaction that either changes the molecular structure of any compound found in the plant Cannabis sativa L. or creates a molecular structure that is not found in the plant Cannabis sativa L."

This definition created immediate controversy. Delta-8 THC exists naturally in cannabis but at concentrations below 1%. When manufacturers convert CBD to delta-8 THC through isomerization, they argue the resulting compound is not "synthetically derived" because its molecular structure occurs in the plant. The DEA has not issued clarifying guidance or pursued enforcement actions to test this interpretation in court, leaving the legal status ambiguous.

In contrast, THCA clearly occurs naturally in cannabis plants at high concentrations. Hemp cultivars with 20% THCA and 0.2% delta-9 THC contain only naturally occurring cannabinoids, making the "synthetically derived" restriction inapplicable. This distinction has made THCA products more legally defensible than delta-8 THC, though both exploit the same statutory gap.

FDA Authority and Enforcement

The Food and Drug Administration maintains that all cannabinoid products intended for human or animal consumption require FDA approval under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.). The agency's position, articulated in guidance documents and warning letters, is that cannabinoids are excluded from the dietary supplement definition under 21 U.S.C. § 321(ff)(3)(B) because they were investigated as drugs before being marketed as supplements.

However, the FDA has issued only 23 warning letters to hemp-derived THC manufacturers between 2020 and 2025, primarily targeting companies making therapeutic claims rather than addressing the products' intoxicating nature. In congressional testimony in May 2024, FDA Commissioner Robert Califf stated that "the agency lacks sufficient resources to comprehensively regulate the thousands of hemp-derived cannabinoid products on the market" and called for "clear statutory authority and appropriations to establish a regulatory framework for these products."

State Legislative Approaches

States have adopted four primary regulatory strategies to address the loophole. The first approach, taken by Alaska, Arkansas, and Montana, explicitly schedules delta-8 THC and other hemp-derived intoxicating cannabinoids as controlled substances, effectively prohibiting their sale. These states argue that their controlled substances laws operate independently of federal hemp policy and that the Farm Bill does not preempt state drug scheduling.

The second approach, implemented by Oregon and Colorado, requires hemp-derived intoxicating products to be sold only through state-licensed cannabis retailers subject to testing, packaging, and taxation requirements. Oregon's House Bill 3000, effective January 2024, defined "adult use cannabis items" to include "any hemp product or hemp extract that is intended for human consumption or inhalation and contains a cannabinoid that is intoxicating," requiring such products to enter the regulated cannabis supply chain.

The third approach establishes hemp-specific regulations short of full cannabis licensing. Minnesota's Hemp-Derived Consumer Products law, enacted in May 2023, created a regulatory framework allowing hemp-derived THC products with limits of 5mg THC per serving and 50mg per package, sold only to adults 21 and older through licensed retailers. The law requires testing, childproof packaging, and labeling standards while keeping hemp products separate from the state's adult-use cannabis program.

The fourth approach, seen in Texas and North Carolina, involves legislative gridlock where lawmakers cannot agree on restrictions, leaving the market largely unregulated. This outcome often results from conflict between hemp industry interests, cannabis industry advocates, and public health stakeholders, each pushing different regulatory models.

State-by-State Breakdown

States with Comprehensive Bans

Alaska amended its controlled substances schedule in May 2021 to include "synthetically derived cannabinoids," effectively prohibiting delta-8 THC and similar compounds. Possession limits for legal cannabis (one ounce for adults 21+) do not apply to hemp-derived THC products, which are treated as controlled substances. Enforcement began in September 2021.

Arkansas added delta-8 THC and delta-10 THC to its Schedule VI controlled substances in September 2021. The state's medical marijuana program remains separate, with 38 licensed dispensaries serving approximately 88,000 registered patients as of June 2025. Hemp-derived intoxicating products cannot be sold legally.

Colorado determined in June 2021 that delta-8 THC products must be sold through licensed marijuana retailers. The state's Marijuana Enforcement Division issued guidance that "any artificially derived cannabinoid is subject to regulation as marijuana." High-THCA hemp flower is similarly restricted. Colorado's adult-use program, operational since 2014, includes over 500 licensed dispensaries.

Delaware prohibited the sale of delta-8 THC and "other intoxicating hemp-derived cannabinoids" in July 2022. The state legalized adult-use cannabis in April 2023, with retail sales beginning in March 2025. Hemp-derived THC products remain prohibited outside the licensed cannabis framework.

Montana banned delta-8 THC sales in May 2021, shortly after launching its adult-use cannabis program. The state's Department of Public Health and Human Services issued emergency rules classifying delta-8 as a Schedule I controlled substance. Possession limits for legal cannabis are one ounce for adults 21+, with 350+ licensed dispensaries statewide as of June 2025.

States Requiring Cannabis Licensing

Oregon requires all inhalable hemp products and hemp products containing intoxicating cannabinoids to be sold through Oregon Liquor and Cannabis Commission-licensed retailers as of January 2024. House Bill 3000 established this framework, subjecting hemp-derived THC products to the same testing, packaging, and taxation requirements as cannabis. The state has 750+ licensed cannabis retailers.

Washington issued guidance in March 2022 that delta-8 THC and high-THCA products must be sold through state-licensed cannabis retailers. The Washington State Liquor and Cannabis Board determined that "any product containing THC in any form intended for human consumption is a marijuana product" under state law. The state's adult-use program includes 500+ licensed retailers.

States with Hemp-Specific Regulations

Minnesota enacted comprehensive hemp-derived cannabinoid regulations in May 2023, allowing products with up to 5mg THC per serving and 50mg per package. The law, codified in Minnesota Statutes § 151.72, requires third-party testing, childproof packaging, and sales only to adults 21+. Over 1,200 retailers have registered to sell compliant products. The state separately legalized adult-use cannabis in May 2023, with retail sales expected to begin in 2026.

Louisiana passed Act 164 in June 2024, creating a regulatory framework for hemp-derived THC products with a 0.3% total THC limit (including THCA after conversion). The law requires testing, labeling, and age restrictions but allows sales outside the state's medical marijuana program. Implementation began in January 2025.

Utah enacted regulations in March 2023 limiting hemp-derived THC products to 0.3% total THC and prohibiting inhalable forms. The state's Department of Agriculture and Food oversees compliance. Utah's medical cannabis program, established in 2020, operates separately with 15 licensed dispensaries serving approximately 35,000 registered patients.

States with Active Legislative Battles

South Carolina saw legislative efforts to restrict hemp-derived THC products fail in June 2025 when the House and Senate could not agree on THC limits and regulatory structure. The House proposed a 0.3% total THC limit, while the Senate sought to allow up to 5mg per serving. The impasse left the market unregulated, with hemp-derived products available in convenience stores, smoke shops, and online retailers throughout the state.

Texas remains in legal limbo following court decisions blocking the Department of State Health Services' attempted ban. Legislation introduced in the 2025 session to establish a regulatory framework failed to advance. As of June 2025, hemp-derived THC products are widely available with no state-level restrictions beyond the federal 0.3% delta-9 THC limit. The state's medical cannabis program remains highly restrictive, limited to low-THC products for specific conditions.

North Carolina has seen multiple legislative proposals to regulate hemp-derived THC products fail since 2022. The state's hemp industry, valued at over $2 billion, has successfully lobbied against restrictions. High-THCA hemp flower is openly sold in smoke shops and hemp retailers across the state. North Carolina has no legal cannabis program beyond a limited medical CBD law.

Ohio voters approved adult-use cannabis legalization in November 2023, with retail sales beginning in August 2024. However, hemp-derived THC products remain in a gray area as regulators determine whether they fall under the new cannabis framework or remain unregulated hemp. The Division of Cannabis Control has not issued definitive guidance as of June 2025.

States with Minimal Restrictions

Florida has not enacted state-level restrictions on hemp-derived THC products beyond the federal definition. The state's hemp program, overseen by the Department of Agriculture and Consumer Services, focuses on agricultural compliance. Hemp-derived products are sold in gas stations, smoke shops, and online throughout the state. Florida's medical marijuana program serves over 900,000 registered patients through 600+ dispensaries, while adult-use legalization appeared on the November 2024 ballot but failed to achieve the required 60% threshold.

Georgia allows hemp-derived THC products that comply with the federal 0.3% delta-9 THC definition. The state's hemp program, established in 2019, does not restrict THCA concentrations or regulate downstream products. Georgia has a limited low-THC medical cannabis program but no adult-use market.

Tennessee has become a major producer of high-THCA hemp flower, with cultivators openly breeding genetics that produce marijuana-like effects while remaining compliant with federal testing protocols. The state has not enacted restrictions beyond federal law. Tennessee's medical cannabis program, approved in 2021, is limited to specific conditions and has not yet begun retail operations as of June 2025.

Market and Business Implications

Industry Size and Growth Trajectory

The hemp-derived THC market grew from near zero in 2019 to an estimated $28 billion in 2024, according to analysis by Whitney Economics and the Brightfield Group. This figure includes delta-8 THC products ($9 billion), high-THCA flower ($12 billion), delta-10 THC, THC-O, HHC, and other novel cannabinoids ($4 billion), and THCA concentrates and vapes ($3 billion). The market's compound annual growth rate of 187% between 2020 and 2024 far exceeded the legal cannabis industry's 23% CAGR over the same period.

Distribution channels differ markedly from state-licensed cannabis. Approximately 65% of hemp-derived THC sales occur through convenience stores, gas stations, and smoke shops, compared to less than 1% for legal cannabis. Online sales account for 25% of the hemp-derived market versus 8% for legal cannabis. This distribution advantage stems from hemp's federal legal status, which allows interstate commerce and credit card processing—luxuries unavailable to cannabis businesses operating under the Controlled Substances Act.

Impact on Licensed Cannabis Operators

Multi-state operators have reported measurable revenue impacts in states with unregulated hemp competition. Trulieve, Florida's dominant medical marijuana operator, noted in its Q1 2025 earnings call that "hemp-derived product proliferation has created pricing pressure and customer confusion in our core Florida market." The company's Florida same-store sales declined 18% year-over-year in the first quarter of 2025.

The competitive disadvantage extends beyond market share to fundamental economics. Licensed cannabis operators face effective federal tax rates exceeding 70% under Internal Revenue Code Section 280E, which prohibits businesses trafficking in Schedule I substances from deducting ordinary business expenses. Hemp companies, operating legally under federal law, deduct rent, salaries, marketing, and other expenses, creating a 40-50 percentage point tax advantage. A licensed dispensary in Illinois pays approximately $3.2 million in federal taxes on $10 million in revenue, while a hemp retailer with identical revenue pays approximately $800,000.

Capital access represents another asymmetry. Hemp businesses can access traditional banking, Small Business Administration loans, and equity financing from institutional investors. Cannabis operators remain largely excluded from banking services and rely on high-cost private debt or equity dilution. This dynamic has led some MSOs to explore acquiring hemp businesses or launching hemp divisions, though such strategies risk regulatory complications and brand dilution.

Wholesale Market Dynamics

Hemp-derived THC products have disrupted wholesale cannabis pricing, particularly for flower and concentrates. In Oregon, wholesale cannabis flower prices fell from an average of $1,200 per pound in January 2020 to $450 per pound in June 2025, a decline industry analysts partly attribute to competition from high-THCA hemp flower selling